US FDA approves atezolizumab as first-line monotherapy for adults with metastatic non-small cell lung cancer whose tumours have high PD-L1 expression or PD-L1 stained tumor-infiltrating covering ≥ 10% of tumour area

Approval is based on an interim analysis from the phase III IMpower110 study, which showed that atezolizumab monotherapy improved overall survival by 7.1 months compared with chemotherapy (median 20.2 versus 13.1 months; HR 0.59, 95% CI: 0.40–0.89; p=0.0106).


Biospace Inc.